Locally Advanced HER2-Negative Breast Carcinoma
1 clinical trials · Condition
◉ Watch Locally Advanced HER2-Negative Breast Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (NCT06590558) | National Cancer Institute (NCI) | 2025-08-04 |
Track Locally Advanced HER2-Negative Breast Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.